Conflict of interest
Janssen-Cillag, Novocure
UH has received lecture and/or advisory board honoraria from Medac, Novartis, Daichii-Sankyo, Noxxon, AbbVie, Bayer, Janssen, and Karyopharm. CS has received lecture or advisory board honoraria from AbbVie, Bristol-Myers Squibb, HRA Pharma, Medac, Roche, and Seagen. GT has received lecture, consultant or advisory board honoraria from AbbVie, Bayer, Boehringer Ingelheim, Medac, Novartis, Novocure) and research grants from Roche Diagnostics and Medac. JS has received lecture and/or advisory board honoraria or travel cost reimbursement from Abbvie, Medac, Med-Update, Roche, Novocure and Seagen. MGs reports personal fees from Roche, Novartis, Daichi Sankyo, Novocure, Bayer, frm Janssen-Cillag, Merck, Kyowa Kirin, Seagen, and grants from Novocure. FSG reports advisory board honoraria from Novocure. GT has served on advisory boards of AbbVie, Bayer, Boehringer Ingelheim, received consulting fees from AbbVie, Bayer; received speaker fees from Medac and Novocure. FR has received lecture and/or consulting honoraria from Stryker, Brainlab, Spineart, Icotec, royalties from Spineart and research support from Icotec. The other authors declare they have no financial interests.